Janne G Lyngby1, Michael H Court1, Pamela M Lee2. 1. Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical Sciences, College of Veterinary Medicine, PO Box 647060, Washington State University, WA 99164-7060, USA. 2. Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical Sciences, College of Veterinary Medicine, PO Box 647060, Washington State University, WA 99164-7060, USA. Electronic address: pamelamlee@vetmed.wsu.edu.
Abstract
INTRODUCTION: The clopidogrel active metabolite (CAM) is unstable and challenging to quantitate. The objective was to validate a new method for stabilization and quantitation of CAM, clopidogrel, and the inactive metabolites clopidogrel carboxylic acid and 2-oxo-clopiodgrel in feline plasma. ANIMALS: Two healthy cats administered clopidogrel to demonstrate assay in vivo utility. MATERIALS AND METHODS: Stabilization of CAM was achieved by adding 2-bromo-3'methoxyacetophenone to blood tubes to form a derivatized CAM (CAM-D). Method validation included evaluation of calibration curve linearity, accuracy, and precision; within and between assay precision and accuracy; and compound stability using spiked blank feline plasma. Analytes were measured by high performance liquid chromatography with tandem mass spectrometry. In vivo utility was demonstrated by a pharmacokinetic study of cats given a single oral dose of 18.75mg clopidogrel. RESULTS: The 2-oxo-clopidogrel metabolite was unstable. Clopidogrel, CAM-D, and clopidogrel carboxylic acid appear stable for 1 week at room temperature and 9 months at -80°C. Standard curves showed linearity for CAM-D, clopidogrel, and clopidogrel carboxylic acid (r > 0.99). Between assay accuracy and precision was ≤2.6% and ≤7.1% for CAM-D and ≤17.9% and ≤11.3% for clopidogrel and clopidogrel carboxylic acid. Within assay precision for all three compounds was ≤7%. All three compounds were detected in plasma from healthy cats receiving clopidogrel. DISCUSSION: This methodology is accurate and precise for simultaneous quantitation of CAM-D, clopidogrel, and clopidogrel carboxylic acid in feline plasma but not 2-oxo-clopidogrel. CONCLUSIONS: Validation of this assay is the first step to more fully understanding the use of clopidogrel in cats.
INTRODUCTION: The clopidogrel active metabolite (CAM) is unstable and challenging to quantitate. The objective was to validate a new method for stabilization and quantitation of CAM, clopidogrel, and the inactive metabolites clopidogrel carboxylic acid and 2-oxo-clopiodgrel in feline plasma. ANIMALS: Two healthy cats administered clopidogrel to demonstrate assay in vivo utility. MATERIALS AND METHODS: Stabilization of CAM was achieved by adding 2-bromo-3'methoxyacetophenone to blood tubes to form a derivatized CAM (CAM-D). Method validation included evaluation of calibration curve linearity, accuracy, and precision; within and between assay precision and accuracy; and compound stability using spiked blank feline plasma. Analytes were measured by high performance liquid chromatography with tandem mass spectrometry. In vivo utility was demonstrated by a pharmacokinetic study of cats given a single oral dose of 18.75mg clopidogrel. RESULTS: The 2-oxo-clopidogrel metabolite was unstable. Clopidogrel, CAM-D, and clopidogrel carboxylic acid appear stable for 1 week at room temperature and 9 months at -80°C. Standard curves showed linearity for CAM-D, clopidogrel, and clopidogrel carboxylic acid (r > 0.99). Between assay accuracy and precision was ≤2.6% and ≤7.1% for CAM-D and ≤17.9% and ≤11.3% for clopidogrel and clopidogrel carboxylic acid. Within assay precision for all three compounds was ≤7%. All three compounds were detected in plasma from healthy cats receiving clopidogrel. DISCUSSION: This methodology is accurate and precise for simultaneous quantitation of CAM-D, clopidogrel, and clopidogrel carboxylic acid in feline plasma but not 2-oxo-clopidogrel. CONCLUSIONS: Validation of this assay is the first step to more fully understanding the use of clopidogrel in cats.
Authors: Cody J Peer; Shawn D Spencer; Dustin A H VanDenBerg; Michael A Pacanowski; Richard B Horenstein; William D Figg Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2011-11-26 Impact factor: 3.205
Authors: Giuseppe Patti; Annunziata Nusca; Fabio Mangiacapra; Laura Gatto; Andrea D'Ambrosio; Germano Di Sciascio Journal: J Am Coll Cardiol Date: 2008-09-30 Impact factor: 24.094
Authors: Shlomi Matetzky; Boris Shenkman; Victor Guetta; Michael Shechter; Roy Beinart; Roy Bienart; Ilan Goldenberg; Ilya Novikov; Hanna Pres; Naphtali Savion; David Varon; Hanoch Hod Journal: Circulation Date: 2004-06-07 Impact factor: 29.690
Authors: Marta Karaźniewicz-Łada; Dorota Danielak; Paweł Burchardt; Lukasz Kruszyna; Anna Komosa; Maciej Lesiak; Franciszek Główka Journal: Clin Pharmacokinet Date: 2014-02 Impact factor: 6.447
Authors: Alison J Gareau; Colin Brien; Simon Gebremeskel; Robert S Liwski; Brent Johnston; Michael Bezuhly Journal: Clin Exp Metastasis Date: 2018-01-11 Impact factor: 5.150
Authors: Lei Xu; Ran Li; Juan Li; Zhou Dong; Jiaxin Zong; Chuchu Tan; Zekang Ye; Lu Shi; Xiaoxuan Gong; Chunjian Li Journal: J Biomed Res Date: 2022-02-28